Markus Wosle

Dessau, ST, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.

Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.

Journal: Molecular & cellular oncology

Published: September 26, 2025

Ruthenium-106 brachytherapy and central uveal melanoma.

Ruthenium-106 brachytherapy and central uveal melanoma.

Journal: International ophthalmology

Published: August 10, 2024

Adjuvant Brachytherapy with Ruthenium-106 to Reduce the Risk of Recurrence of Conjunctival Melanoma after Excision.

Adjuvant Brachytherapy with Ruthenium-106 to Reduce the Risk of Recurrence of Conjunctival Melanoma after Excision.

Journal: Ocular oncology and pathology

Published: February 17, 2024

Repeated Radiation Therapy of Recurrent Solitary Fibrous Tumors of the Brain: A Medical Case History Over 20 Years.

Repeated Radiation Therapy of Recurrent Solitary Fibrous Tumors of the Brain: A Medical Case History Over 20 Years.

Journal: Advances in radiation oncology

Published: May 03, 2023

Impact of tumour volume and treatment delay on the outcome after linear accelerator-based fractionated stereotactic radiosurgery of uveal melanoma.

Impact of tumour volume and treatment delay on the outcome after linear accelerator-based fractionated stereotactic radiosurgery of uveal melanoma.

Journal: The British journal of ophthalmology

Published: October 22, 2022

Feasibility of aponeurectomy in combination with perioperative 192Ir high dose rate brachytherapy for Dupuytren's disease.

Feasibility of aponeurectomy in combination with perioperative 192Ir high dose rate brachytherapy for Dupuytren's disease.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: January 23, 2021

Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.

Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.

Journal: BMC cancer

Published: June 25, 2020

The superficially averaged dose gradient at the target volume's boundary: A two-dimensional formulation and solution of anisotropic dose gradient problems.

The superficially averaged dose gradient at the target volume's boundary: A two-dimensional formulation and solution of anisotropic dose gradient problems.

Journal: Zeitschrift fur medizinische Physik

Published: May 12, 2019

Stereotactic radiotherapy for choroidal melanomas by means of HybridArc™ : Physics and technique of linac-based photon beam therapy.

Stereotactic radiotherapy for choroidal melanomas by means of HybridArc™ : Physics and technique of linac-based photon beam therapy.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: January 28, 2018

Optimizing radiosurgery with photons for ocular melanoma.

Optimizing radiosurgery with photons for ocular melanoma.

Journal: Physics and imaging in radiation oncology

Published: August 14, 2017

Standardization of the target volume for boost or partial breast radiation therapy after lumpectomy of breast cancer.

Standardization of the target volume for boost or partial breast radiation therapy after lumpectomy of breast cancer.

Journal: International journal of radiation oncology, biology, physics

Published: February 19, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026